Difficulty: Medium
Average Score: 73%
Practice
A 54-year-old man with seizure disorder and chronic neuropathic pain presents to his primary care physician for follow-up. Review of his laboratory studies indicates elevated liver function tests to four times the normal levels. Which of the following agents would be preferred to manage this patient?
Correct answer
D
Rationale
In this scenario, the preferred agent to manage the patient with elevated liver function tests due to seizure disorder and chronic neuropathic pain would be option D) Pregabalin. Pregabalin is a medication used to treat neuropathic pain and seizures, and it is primarily excreted unchanged by the kidneys, making it a safer choice for patients with liver impairment as it does not require hepatic metabolism for elimination.
Option A) Carbamazepine, option B) Phenobarbital, and option C) Phenytoin are all antiepileptic drugs that are metabolized in the liver. In the case of a patient with elevated liver function tests, using these medications can further burden the already compromised liver function and potentially worsen the condition. Carbamazepine, Phenobarbital, and Phenytoin are known to induce liver enzymes and can lead to hepatotoxicity in patients with liver dysfunction.
Educationally, understanding the pharmacokinetics and pharmacodynamics of CNS drugs is crucial for healthcare professionals when managing patients with comorbidities such as liver impairment. It is essential to consider the organ functions of patients when selecting medications to minimize adverse effects and ensure optimal therapeutic outcomes. Pregabalin, with its renal excretion pathway, provides a safer alternative in this clinical scenario, highlighting the importance of individualized pharmacotherapy based on patient-specific factors.
Option A) Carbamazepine, option B) Phenobarbital, and option C) Phenytoin are all antiepileptic drugs that are metabolized in the liver. In the case of a patient with elevated liver function tests, using these medications can further burden the already compromised liver function and potentially worsen the condition. Carbamazepine, Phenobarbital, and Phenytoin are known to induce liver enzymes and can lead to hepatotoxicity in patients with liver dysfunction.
Educationally, understanding the pharmacokinetics and pharmacodynamics of CNS drugs is crucial for healthcare professionals when managing patients with comorbidities such as liver impairment. It is essential to consider the organ functions of patients when selecting medications to minimize adverse effects and ensure optimal therapeutic outcomes. Pregabalin, with its renal excretion pathway, provides a safer alternative in this clinical scenario, highlighting the importance of individualized pharmacotherapy based on patient-specific factors.